Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 17Multiple Myeloma 12Ovarian Neoplasms 9Recurrence 8Lymphoma, B-Cell 8Pancreatic Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma 7Hodgkin Disease 7Burkitt Lymphoma 7Colorectal Neoplasms 6Myeloproliferative Disorders 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Biphenotypic, Acute 5Stomach Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urogenital Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Osteosarcoma 3Melanoma 3Lymphoma, Follicular 3Leukemia, B-Cell 3

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Autoimmune Diseases of the Nervous System × fludarabine × 30 days × Clear all
NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Tongji Hospital

Phase 1 Recruiting
6 enrolled

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡